No black box warning on record for Duvyzat

As of the latest FDA labeling reviewed, Duvyzat (GIVINOSTAT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Duvyzat medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression, including anemia and neutropenia. Monitor platelets; dosage adjustment or discontinuation may be needed. ( 2.3 , 5.1 ) Increased Triglycerides: An increase in triglycerides can occur; dosage modification may be needed. Discontinuation may be needed. ( 2.3 , 5.2 ) G

No black box warning on record for Duvyzat

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression, including anemia and neutropenia. Monitor platelets; dosage adjustment or discontinuation may be needed. ( 2.3 , 5.1 ) Increased Triglycerides: An increase in triglycerides can occur; dosage modification may be needed. Discontinuation may be needed. ( 2.3 , 5.2 ) G

Duvyzat Black Box Warning

No black box warning on record for Duvyzat

Other warnings & precautions

Duvyzat Black Box Warning

No black box warning on record for Duvyzat

Other warnings & precautions